Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
A Safety and Tolerability Study of Jaktinib
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 26
- Registration Number
- NCT05279001
- Locations
- 🇺🇸
Site 01, Canton, Ohio, United States
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 315
- Registration Number
- NCT05255237
- Locations
- 🇨🇳
11 Xizhimen South Street, Beijing, Beijing, China
ADME Study of [14C]-Jaktinib in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Adult Male Volunteers
- Interventions
- Drug: [14C]-Jaktinib
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT05150717
- Locations
- 🇨🇳
The First Affiliated Hospital of soochow University, Suzhou, Jiangsu, China
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 425
- Registration Number
- NCT05051761
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Hospital for Skin Diseases, Chinese Academy of medical Sciences, Nanjing, Jiangsu, China
Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function
Phase 1
Completed
- Conditions
- Healthy SubjectsHepatic Insufficiency
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT04993404
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Phase 3
Completed
- Conditions
- Differentiated Thyroid Cancer
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 201
- Registration Number
- NCT04971473
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Phase 2
Not yet recruiting
- Conditions
- Acute Graft-Versus-Host Disease
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT04971551
- Locations
- 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Phase 3
Recruiting
- Conditions
- Differentiated Thyroid Cancer
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 328
- Registration Number
- NCT04964284
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Phase 1
Terminated
- Conditions
- Myelodysplastic SyndromesMyeloproliferative NeoplasmsMyelofibrosis
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 1
- Registration Number
- NCT04866056
- Locations
- 🇨🇳
79 Qingchun Road, Hangzhou, Zhejiang, China
Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT04851535
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China